RECRUITING

Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this study is to determine whether a palliative care intervention (PEACE) can improve the quality of life and experiences of participants with Lymphoma, Leukemia, or Multiple Myeloma receiving adoptive cellular therapy (ACT). After completion of an open pilot, participants will be randomly assigned into one of two study intervention groups. The names of the study intervention groups involved in this study are: * Palliative care (PEACE) plus usual oncology care * Usual care (standard oncology care) Participation in this research study is expected to last for up to 2 years. It is expected that about 90 people will take part in this research study.

Official Title

Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy: The PEACE Study

Quick Facts

Study Start:2022-12-30
Study Completion:2027-04-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05646576

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age 18 years or older.
  2. * Ability to complete surveys in English or with assistance of an interpreter.
  3. * Diagnosis of a hematologic malignancy.
  4. * Receiving autologous adoptive cellular therapy (ACT) at MGH with an FDA approved cellular therapy product.
  1. * Impaired cognition or uncontrolled mental illness that prohibits study compliance based on the oncology clinician assessment.
  2. * Already receiving palliative care (PC).

Contacts and Locations

Study Contact

Patrick C Johnson
CONTACT
617-724-4000
PCJOHNSON@MGH.HARVARD.EDU

Principal Investigator

Patrick C Johnson, MD
PRINCIPAL_INVESTIGATOR
Massachusetts General Hospital

Study Locations (Sites)

Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02215
United States

Collaborators and Investigators

Sponsor: Massachusetts General Hospital

  • Patrick C Johnson, MD, PRINCIPAL_INVESTIGATOR, Massachusetts General Hospital

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-12-30
Study Completion Date2027-04-01

Study Record Updates

Study Start Date2022-12-30
Study Completion Date2027-04-01

Terms related to this study

Keywords Provided by Researchers

  • Hematologic Malignancy
  • Adoptive Cellular Therapy
  • Palliative Care Intervention
  • Lymphoma
  • Leukemia
  • Multiple Myeloma
  • Palliative Care

Additional Relevant MeSH Terms

  • Hematologic Malignancy
  • Blood Cancer
  • Lymphoma
  • Leukemia
  • Multiple Myeloma